A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma

Authors

Keywords

Journal

Volume 134, Issue 12, Pages 1325-1335

Publisher

Springer Nature

Online

2008-05-26

DOI

10.1007/s00432-008-0406-2

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started